S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   153.00 (-0.16%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
T   38.24 (-0.29%)
AMD   41.15 (-3.38%)
ACB   2.62 (+0.77%)
F   9.22 (-1.07%)
NFLX   298.50 (+0.02%)
DIS   146.37 (-0.94%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   153.00 (-0.16%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
T   38.24 (-0.29%)
AMD   41.15 (-3.38%)
ACB   2.62 (+0.77%)
F   9.22 (-1.07%)
NFLX   298.50 (+0.02%)
DIS   146.37 (-0.94%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   153.00 (-0.16%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
T   38.24 (-0.29%)
AMD   41.15 (-3.38%)
ACB   2.62 (+0.77%)
F   9.22 (-1.07%)
NFLX   298.50 (+0.02%)
DIS   146.37 (-0.94%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   153.00 (-0.16%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
T   38.24 (-0.29%)
AMD   41.15 (-3.38%)
ACB   2.62 (+0.77%)
F   9.22 (-1.07%)
NFLX   298.50 (+0.02%)
DIS   146.37 (-0.94%)
Log in

NASDAQ:QTNT - Quotient Stock Price, Forecast & News

$8.57
-0.19 (-2.17 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$8.52
Now: $8.58
$8.86
50-Day Range
$7.68
MA: $8.38
$9.05
52-Week Range
$5.73
Now: $8.58
$11.30
Volume260,021 shs
Average Volume298,263 shs
Market Capitalization$569.72 million
P/E RatioN/A
Dividend YieldN/A
Beta0.96
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. Read More…

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QTNT
CUSIPN/A
Phone011-41-22-716-9800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$29.13 million
Book Value$0.03 per share

Profitability

Net Income$-105,390,000.00
Net Margins-333.37%

Miscellaneous

EmployeesN/A
Market Cap$569.72 million
Next Earnings Date1/30/2020 (Estimated)
OptionableOptionable

Receive QTNT News and Ratings via Email

Sign-up to receive the latest news and ratings for QTNT and its competitors with MarketBeat's FREE daily newsletter.


Quotient (NASDAQ:QTNT) Frequently Asked Questions

What is Quotient's stock symbol?

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

How were Quotient's earnings last quarter?

Quotient Ltd (NASDAQ:QTNT) issued its earnings results on Monday, November, 4th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.01. The business earned $7.85 million during the quarter, compared to analyst estimates of $6.80 million. View Quotient's Earnings History.

When is Quotient's next earnings date?

Quotient is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for Quotient.

What price target have analysts set for QTNT?

1 analysts have issued 12 month price objectives for Quotient's stock. Their forecasts range from $13.50 to $13.50. On average, they anticipate Quotient's share price to reach $13.50 in the next twelve months. This suggests a possible upside of 57.9% from the stock's current price. View Analyst Price Targets for Quotient.

What is the consensus analysts' recommendation for Quotient?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quotient in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quotient.

Has Quotient been receiving favorable news coverage?

Media headlines about QTNT stock have trended somewhat positive on Friday, according to InfoTrie. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Quotient earned a news impact score of 1.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Quotient.

Are investors shorting Quotient?

Quotient saw a decline in short interest during the month of November. As of November 15th, there was short interest totalling 3,340,000 shares, a decline of 25.1% from the October 31st total of 4,460,000 shares. Based on an average trading volume of 358,700 shares, the short-interest ratio is currently 9.3 days. Currently, 5.8% of the shares of the stock are sold short. View Quotient's Current Options Chain.

Who are some of Quotient's key competitors?

What other stocks do shareholders of Quotient own?

Who are Quotient's key executives?

Quotient's management team includes the folowing people:
  • Mr. Franz Walt, CEO & Director (Age 60)
  • Mr. Jeremy Stackawitz, Pres (Age 44)
  • Mr. Edward Farrell, Pres (Age 49)
  • Mr. Christopher J. Lindop, Chief Financial Officer (Age 61)
  • Mr. John Allan, Corp. Sr. VP & CTO

Who are Quotient's major shareholders?

Quotient's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (0.62%), Quantum Capital Management (0.36%), Castleark Management LLC (0.16%), Barclays PLC (0.05%), California Public Employees Retirement System (0.03%) and Man Group plc (0.03%). Company insiders that own Quotient stock include Brian Mcdonough, Edward Farrell, Frederick Hallsworth, Jeremy Stackawitz, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Prondzynski Heino Von and Roland Boyd. View Institutional Ownership Trends for Quotient.

Which institutional investors are selling Quotient stock?

QTNT stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Quantum Capital Management and Zurcher Kantonalbank Zurich Cantonalbank. Company insiders that have sold Quotient company stock in the last year include Edward Farrell, Jeremy Stackawitz and Roland Boyd. View Insider Buying and Selling for Quotient.

Which institutional investors are buying Quotient stock?

QTNT stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Man Group plc, Cadence Capital Management LLC, Castleark Management LLC, California Public Employees Retirement System and Tower Research Capital LLC TRC. Company insiders that have bought Quotient stock in the last two years include Brian Mcdonough, Frederick Hallsworth, Life Sciences Maste Perceptive, Perceptive Advisors Llc and Prondzynski Heino Von. View Insider Buying and Selling for Quotient.

How do I buy shares of Quotient?

Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Quotient's stock price today?

One share of QTNT stock can currently be purchased for approximately $8.55.

How big of a company is Quotient?

Quotient has a market capitalization of $568.06 million and generates $29.13 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. View Additional Information About Quotient.

What is Quotient's official website?

The official website for Quotient is http://www.quotientbd.com/.

How can I contact Quotient?

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at 011-41-22-716-9800.


MarketBeat Community Rating for Quotient (NASDAQ QTNT)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  269 (Vote Outperform)
Underperform Votes:  270 (Vote Underperform)
Total Votes:  539
MarketBeat's community ratings are surveys of what our community members think about Quotient and other stocks. Vote "Outperform" if you believe QTNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QTNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel